{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=22",
    "query": {
      "condition": "Ovary Disease",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 2268,
    "total_pages": 227,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T01:44:52.336Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003425",
      "title": "Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Leukemia",
        "Lymphoma",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Sarcoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "amifostine trihydrate",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Kentucky",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "14 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "1997-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-04-26",
      "last_synced_at": "2026-10-25T01:44:52.336Z",
      "location_count": 4,
      "location_summary": "Lexington, Kentucky • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003425"
    },
    {
      "nct_id": "NCT04707248",
      "title": "A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Ovarian Tumor"
      ],
      "interventions": [
        {
          "name": "DS-6000a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 179,
      "start_date": "2020-12-22",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-25T01:44:52.336Z",
      "location_count": 6,
      "location_summary": "Tucson, Arizona • Denver, Colorado • Lake Mary, Florida + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04707248"
    },
    {
      "nct_id": "NCT04602117",
      "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2 Low",
        "SYD-985",
        "SYD985",
        "Vic-trastuzumab Duocarmazine",
        "Metastatic Cancer",
        "Metastatic Breast Cancer",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Metastatic",
        "HER2 Low Breast Cancer",
        "GastroEsophageal Cancer",
        "Gastroesophageal Adenocarcinoma",
        "Endometrium Tumor",
        "Ovarian Cancer",
        "Ovarian Carcinoma",
        "HER2-positive Gastric Cancer",
        "HER2-positive Metastatic Breast Cancer",
        "HER2 Mutation-Related Tumors",
        "HER-2 Protein Overexpression",
        "HER2 Low HR Positive",
        "HR Positive",
        "Hormone Receptor-positive Breast Cancer",
        "Estrogen Receptor Positive Tumor",
        "Progesterone Receptor-positive Breast Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor Negative Breast Carcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-07-28",
      "completion_date": "2021-11-17",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-10-25T01:44:52.336Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04602117"
    },
    {
      "nct_id": "NCT04501913",
      "title": "Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage 0 Gastric Cancer AJCC v8",
        "Clinical Stage I Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage I Gastric Cancer AJCC v8",
        "Clinical Stage II Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage II Gastric Cancer AJCC v8",
        "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IIA Gastric Cancer AJCC v8",
        "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IIB Gastric Cancer AJCC v8",
        "Clinical Stage III Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage IVA Gastric Cancer AJCC v8",
        "Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage IVB Gastric Cancer AJCC v8",
        "Hepatobiliary Neoplasm",
        "Malignant Digestive System Neoplasm",
        "Malignant Female Reproductive System Neoplasm",
        "Malignant Genitourinary System Neoplasm",
        "Malignant Neoplasm",
        "Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage 0 Gastric Cancer AJCC v8",
        "Pathologic Stage I Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage I Gastric Cancer AJCC v8",
        "Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IA Gastric Cancer AJCC v8",
        "Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IB Gastric Cancer AJCC v8",
        "Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage II Gastric Cancer AJCC v8",
        "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IIA Gastric Cancer AJCC v8",
        "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IIB Gastric Cancer AJCC v8",
        "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage III Gastric Cancer AJCC v8",
        "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IIIA Gastric Cancer AJCC v8",
        "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IIIB Gastric Cancer AJCC v8",
        "Pathologic Stage IIIC Gastric Cancer AJCC v8",
        "Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IV Gastric Cancer AJCC v8",
        "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8",
        "Stage 0 Colorectal Cancer AJCC v8",
        "Stage 0a Bladder Cancer AJCC v8",
        "Stage 0is Bladder Cancer AJCC v8",
        "Stage I Bladder Cancer AJCC v8",
        "Stage I Cervical Cancer AJCC v8",
        "Stage I Colorectal Cancer AJCC v8",
        "Stage I Ovarian Cancer AJCC v8",
        "Stage I Prostate Cancer AJCC v8",
        "Stage I Renal Cell Cancer AJCC v8",
        "Stage I Uterine Corpus Cancer AJCC v8",
        "Stage IA Cervical Cancer AJCC v8",
        "Stage IA Ovarian Cancer AJCC v8",
        "Stage IA Uterine Corpus Cancer AJCC v8",
        "Stage IA1 Cervical Cancer AJCC v8",
        "Stage IA2 Cervical Cancer AJCC v8",
        "Stage IB Cervical Cancer AJCC v8",
        "Stage IB Ovarian Cancer AJCC v8",
        "Stage IB Uterine Corpus Cancer AJCC v8",
        "Stage IB1 Cervical Cancer AJCC v8",
        "Stage IB2 Cervical Cancer AJCC v8",
        "Stage IC Ovarian Cancer AJCC v8",
        "Stage II Bladder Cancer AJCC v8",
        "Stage II Cervical Cancer AJCC v8",
        "Stage II Colorectal Cancer AJCC v8",
        "Stage II Ovarian Cancer AJCC v8",
        "Stage II Prostate Cancer AJCC v8",
        "Stage II Renal Cell Cancer AJCC v8",
        "Stage II Uterine Corpus Cancer AJCC v8",
        "Stage IIA Cervical Cancer AJCC v8",
        "Stage IIA Colorectal Cancer AJCC v8",
        "Stage IIA Ovarian Cancer AJCC v8",
        "Stage IIA Prostate Cancer AJCC v8",
        "Stage IIA1 Cervical Cancer AJCC v8",
        "Stage IIA2 Cervical Cancer AJCC v8",
        "Stage IIB Cervical Cancer AJCC v8",
        "Stage IIB Colorectal Cancer AJCC v8",
        "Stage IIB Ovarian Cancer AJCC v8",
        "Stage IIB Prostate Cancer AJCC v8",
        "Stage IIC Colorectal Cancer AJCC v8",
        "Stage IIC Prostate Cancer AJCC v8",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Prostate Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage III Uterine Corpus Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Stage IIIA Cervical Cancer AJCC v8",
        "Stage IIIA Colorectal Cancer AJCC v8",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIA Prostate Cancer AJCC v8",
        "Stage IIIA Uterine Corpus Cancer AJCC v8",
        "Stage IIIA1 Ovarian Cancer AJCC v8",
        "Stage IIIA2 Ovarian Cancer AJCC v8",
        "Stage IIIB Bladder Cancer AJCC v8",
        "Stage IIIB Cervical Cancer AJCC v8",
        "Stage IIIB Colorectal Cancer AJCC v8",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIB Prostate Cancer AJCC v8",
        "Stage IIIB Uterine Corpus Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IIIC Prostate Cancer AJCC v8",
        "Stage IIIC Uterine Corpus Cancer AJCC v8",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v8",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Uterine Corpus Cancer AJCC v8",
        "Stage IVA Bladder Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVB Bladder Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Patient Monitoring",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2020-08-11",
      "completion_date": "2025-10-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-25T01:44:52.336Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04501913"
    },
    {
      "nct_id": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Renal Cell Carcinoma",
        "Non-Small Cell Lung Cancer",
        "Castration-resistant Prostate Cancer",
        "Triple Negative Breast Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Hepatocellular Carcinoma",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Differentiated Thyroid Cancer",
        "Lower Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 914,
      "start_date": "2017-09-05",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-25T01:44:52.336Z",
      "location_count": 57,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03170960"
    },
    {
      "nct_id": "NCT00842582",
      "title": "Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Loyola University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2009-02",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-25T01:44:52.336Z",
      "location_count": 2,
      "location_summary": "Maywood, Illinois • Winfield, Illinois",
      "locations": [
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Winfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00842582"
    },
    {
      "nct_id": "NCT04383210",
      "title": "Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Pancreatic Cancer",
        "Lung Cancer",
        "Head and Neck Cancer",
        "Breast Cancer",
        "Kidney Cancer",
        "Colorectal Cancer",
        "Bladder Cancer",
        "Ovarian Cancer",
        "Sarcoma",
        "Gallbladder Cancer",
        "Bile Duct Cancer",
        "Esophageal Cancer",
        "Uterine Cancer",
        "Cholangiocarcinoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Seribantumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevation Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2020-09-29",
      "completion_date": "2024-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-04-03",
      "last_synced_at": "2026-10-25T01:44:52.336Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04383210"
    },
    {
      "nct_id": "NCT00390182",
      "title": "Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastrointestinal Neoplasms",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2003-10",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2020-03-18",
      "last_synced_at": "2026-10-25T01:44:52.336Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00390182"
    },
    {
      "nct_id": "NCT00867659",
      "title": "The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovarian Hyperstimulation Syndrome"
      ],
      "interventions": [
        {
          "name": "Cetrotide acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Center for Reproductive Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "32 Years",
        "sex": "FEMALE",
        "summary": "19 Years to 32 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2009-03",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2013-03-27",
      "last_synced_at": "2026-10-25T01:44:52.336Z",
      "location_count": 1,
      "location_summary": "Reston, Virginia",
      "locations": [
        {
          "city": "Reston",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00867659"
    },
    {
      "nct_id": "NCT00910000",
      "title": "Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2009-06",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2018-09-10",
      "last_synced_at": "2026-10-25T01:44:52.336Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00910000"
    }
  ]
}